Prediction and prevention of small‐for‐gestational‐age neonates: evidence from SPREE and ASPRE

Autor: Nicola Persico, Ranjit Akolekar, Daniel L. Rolnik, Kypros H. Nicolaides, L. C. Poon, M.Y. Tan, S. Cicero, Jacques Jani, C. de Paco Matallana, Mandeep Singh, Walter Plasencia, G. Papaioannou, David Wright, Francisca S. Molina, Argyro Syngelaki, D. Janga, Elena Greco
Rok vydání: 2018
Předmět:
Percentile
fetal growth restriction
0302 clinical medicine
Pre-Eclampsia
Pregnancy
Prenatal Diagnosis
Mass Screening
Pregnancy-Associated Plasma Protein-A
Medicine
small-for-gestational age
030212 general & internal medicine
Uterine artery
Aspirin
Fetal Growth Retardation
030219 obstetrics & reproductive medicine
Radiological and Ultrasound Technology
Obstetrics
Incidence (epidemiology)
Obstetrics and Gynecology
SPREE
General Medicine
Uterine Artery
Infant
Small for Gestational Age
Gestation
Female
medicine.drug
Adult
ASPRE
medicine.medical_specialty
pre-eclampsia
aspirin
first-trimester screening
Birth weight
Gestational Age
Placebo
03 medical and health sciences
Predictive Value of Tests
medicine.artery
Humans
Radiology
Nuclear Medicine and imaging
Placenta Growth Factor
business.industry
Infant
Newborn
medicine.disease
Pregnancy Trimester
First
Reproductive Medicine
Small for gestational age
business
Biomarkers
Platelet Aggregation Inhibitors
Zdroj: Ultrasound in Obstetrics & Gynecology. 52:52-59
ISSN: 1469-0705
0960-7692
DOI: 10.1002/uog.19077
Popis: OBJECTIVES To examine the effect of first-trimester screening for pre-eclampsia (PE) on the prediction of delivering a small-for-gestational-age (SGA) neonate and the effect of prophylactic use of aspirin on the prevention of SGA. METHODS The data for this study were derived from two multicenter studies. In SPREE, we investigated the performance of screening for PE by a combination of maternal characteristics and biomarkers at 11-13 weeks' gestation. In ASPRE, women with a singleton pregnancy identified by combined screening as being at high risk for preterm PE (> 1 in 100) participated in a trial of aspirin (150 mg/day from 11-14 until 36 weeks' gestation) compared to placebo. In this study, we used the data from the ASPRE trial to estimate the effect of aspirin on the incidence of SGA with birth weight 1 in 100. RESULTS In SPREE, screening for preterm PE by a combination of maternal factors, mean arterial pressure, uterine artery pulsatility index and serum placental growth factor identified a high-risk group that contained about 46% of SGA neonates
Databáze: OpenAIRE
Externí odkaz: